Nepafenac Once Daily for Macular Edema - Study 2

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 819 participants.

Also called NCT01872611

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 819 participants (enrolled count) (from the registry)
Sponsor
Alcon Research (from the registry)
Registry
  • NCT NCT01872611
  • EudraCT 2013-001874-12
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01872611. Randomized; double masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2015-05 (actual). Results posted on 2016-08-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Nepafenac Once Daily for Macular Edema - Study 2
Condition
Non-Proliferative Diabetic Retinopathy
Condition
Cataract
Intervention (Drug)
Nepafenac Ophthalmic Suspension, 0.3%
Intervention (Other)
Vehicle
Intervention (Drug)
Prednisolone acetate
Lead sponsor
Alcon Research (class: industry)

Record details

Record id
cardio:ct-nct01872611
Content hash
477227eb6de547bda9093d8e6ae0d2d072b102e8dc87b56eb6c2a6254807bde0